| abstract |
A compound according to Formula I: ** (See formula) ** or a pharmaceutically acceptable salt thereof, wherein Z is halogen-substituted aryloxymethylcarbonyl; A is selected from the group consisting of -CH2- and -O-; B and D are independently selected from the group consisting of hydrogen, halogen, C1-4 haloalkyl and C1-4 haloalkoxy; R1 is selected from the group consisting of hydrogen and an amine protecting group, wherein the amine protecting group is selected from the group consisting of benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl, allyloxycarbonyl, acetamido, and phthalimido; R2 is hydrogen; and R3 is selected from the group consisting of C6-10 aryl, 5 to 12 membered heteroaryl, C1-8 alkyl, C3-8 cycloalkyl, 5 to 12 membered saturated heterocyclyl, -L-R5, and -OR6, where L is selected from the group consisting of -O-, -NR-, C 1-4 alkylene and 2- to 4-membered heteroalkylene, wherein R is selected from the group consisting of hydrogen and C 1-8 alkyl, R5 is selected from the group consisting of consists of C6-10 aryl, 5- to 12-membered heteroaryl, C3-8 cycloalkyl, and saturated 5- to 12-membered heterocyclyl, and -OR6 and the carbonyl to which it is attached form an amine protecting group where the amine protecting group is selected from the group consisting of benzyloxycarbonyl, 9-fluorenylmethyloxycarbonyl, tert-butyloxycarbonyl, and allyloxycarbonyl, and wherein R3 is optionally substituted with one or more substituents selected from the group consisting of halo, -CN, -NO2, -N3, -OH , Ra, Rb, -ORa, -ORb, - (CH2) kC (O) RC, -NRd (CH2) uC (O) Rc, -O (CH2) uC (O) Rc, - (CH2) kCONRdRd, - (CH2) kNRdC (O) Rc, -NRd (CH2) uCONRdRd, -NRd (CH2) uNRdC (O) Rc, -O (CH2) uCONRdRd - O (CH2) uNRdC (O) Rc, - (CH2) kS (O) 2NRdRd , - (CH2) kNRdS (O) 2Rc, - (CH2) kS (O) 2Rc, - (CH2) kS (O) Rc, - (CH2) kSRd, - NRd (CH2) uS (O) 2NRdRd, -NRd (CH2) uNRdS (O) 2Rc, -NRd (CH2) uS (O) 2Rc, -NRd (CH2) uS (O) Rc, -NRd (CH2) uSRd, - O (CH2) uS (O) 2NRdRd, - O (CH2) uNRdS (O) 2Rc, -O (CH2) uS (O) 2Rc, -O (CH2) uS (O) Rc and -O (CH2) uSRc, where: each Ra is independently selected from the group that consists of C1-4 alkyl and C1-4 haloalkyl, each Rb is independently selected from the group consisting of C3-6 cycloalkyl, C3-6 halocycloalkyl, C6-10 aryl, 5 to 12 membered heteroaryl, and 5 to 12 saturated heterocyclyl elements, each Rc is independently selected from the group consisting of -OH, C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, C3-8 halocycloalkyl, C6-10 aryl, (C6-10 aryl) - (C1-8 alkyl -8), 5 to 12 membered heteroaryl, and 5 to 12 membered saturated heterocyclyl, each Rd is independently selected from the group consisting of hyd rogen and C 1-8 alkyl, each subscript k is independently selected from 0, 1, 2, 3, 4, 5, and 6 and each subscript u is independently selected from 1, 2, 3, 4, 5, and 6; and R4 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4 haloalkoxy; provided that when Z is substituted phenoxymethylcarbonyl, A is -CH2- and B and D are hydrogen, then R3 is different from (2-phenyl) ethyl or substituted (2-phenyl) ethyl. |